No Data
Northeast Pharmaceutical's Subsidiary Gets Nod to Market Levocarnitine Oral Solution
Northeast Pharmaceutical Group (000597.SZ): Fangda Steel has cumulatively increased its shareholding in the company by 1.5175 million shares.
Northeast Pharmaceutical Group (000597.SZ) announced that on April 15, 2025, the company received a unanimous decision from the controlling shareholder...
Northeast Pharmaceutical Group (000597.SZ): Subsidiary obtains pharmaceutical registration certificate for Levetiracetam Extended-Release Tablets.
On April 9, Gelonghui reported that Northeast Pharmaceutical Group (000597.SZ) announced that recently, its wholly-owned subsidiary, Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd., received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration (Acceptance No.: CYHS2301768, Certificate No.: 2025S00826). Levetiracetam is a pyrrolidine derivative. In vitro and in vivo experiments show that levetiracetam can inhibit hippocampal seizure-like discharge, without affecting the excitability of normal neurons, suggesting that levetiracetam may selectively inhibit seizure-like discharge.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely
Tohoku Pharmaceutical: 2024 Annual Report Summary
